Updated:
Swiss Health Angels
Swiss Health Angels backs early-stage European health ventures from Basel, targeting Seed and Start-up rounds in digital health and medical devices.
Swiss Health Angels
Swiss Health Angels invests from Basel, a city defined by the gravitational pull of Roche and Novartis. The firm targets Seed and Start-up rounds across Europe, with a mandate covering digital health platforms, diagnostic tools, and medical-device innovators. It operates through direct co-investments and venture commitments rather than managing a blind pool of discretionary capital, which gives its limited partners line-of-sight into each underlying asset. Its confirmed strategy spans early-stage venture and co-investment vehicles, reflecting a model designed to pair private risk capital with the technical diligence infrastructure that flows naturally from Basel's research universities and corporate R&D hubs. The deployment cadence remains undisclosed in aggregate, but the firm's public posture indicates a steady pace of small-ticket Seed and Series A checks across Switzerland, Germany, and the broader European life-sciences corridor. The fund structure leans toward syndicated rounds where Swiss Health Angels joins lead investors in issues sourced through academic spin-out networks and industry conferences. Portfolio-level detail is not systematically published. The geographic footprint concentrates on western and central Europe, leveraging proximity to ETH Zurich, EPFL, and the Upper Rhine life-sciences cluster. The firm's most recent verifiable activity predates the current reporting window, and the absence of a regularly updated public site or LinkedIn presence obscures team scale and recent closes. The choice to maintain a low-profile operational stance is characteristic of Swiss private investment vehicles that raise capital from a tight circle of HNWIs and family-owned holding companies rather than pursuing institutional fund marketing. This architecture typically embeds governance through direct LP advisory boards rather than open-ended fund structures, aligning with Swiss private-equity norms.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Basel
Corporate office
Basel-Town, Switzerland
Sector focus
Frequently asked questions
What investment stages does Swiss Health Angels target?
The firm concentrates on Seed and early Start-up rounds, as reflected in its stated strategy. It engages primarily through co-investment structures alongside lead venture investors in the health and life-sciences sectors. The focus is on first institutional checks rather than growth equity or late-stage venture.
How does Swiss Health Angels source its deal flow?
Operating from Basel, the firm draws on its proximity to Europe's densest pharmaceutical cluster — Roche and Novartis are headquartered in the same city — along with spillover from ETH Zurich and the University of Basel. This positioning supports a sourcing model built on academic spin-outs, C-suite networks, and specialized life-sciences venture syndicates.
Does Swiss Health Angels invest only in Switzerland?
No. While Basel is its home base, the firm's mandate covers Europe broadly, with activity recorded in Germany and the wider life-sciences corridor. The investment team typically co-invests in syndicated rounds that draw together cross-border participants, giving it exposure to start-ups across multiple European jurisdictions.
Is Swiss Health Angels a single family office?
Swiss Health Angels is structured as an asset manager rather than a single-family office, focusing on private equity in the health sector. Its investor base likely includes high-net-worth individuals and family-owned holding companies, a common profile for Swiss private investment firms that do not publicly market institutional fund vehicles.
Which sectors does Swiss Health Angels explicitly avoid?
No explicit exclusion list is published. However, the firm's mandate centers on health — digital health, medical devices, and diagnostics — suggesting it does not invest in unrelated industries such as enterprise software, fintech, or clean energy unless they serve the healthcare vertical. This sector concentration is the defining feature of its strategy.
Does Swiss Health Angels participate in fund commitments or only direct deals?
Swiss Health Angels engages in both direct co-investments and venture fund commitments. The strategy notes Venture (General) alongside Co-Investment and Early Stage approaches, indicating a blended model where the firm can participate as a direct investor in individual start-ups while also committing capital to specialized venture funds.
How is the firm governed, given its limited public presence?
Swiss private investment vehicles of this type typically rely on a close network of limited partners and direct advisory-board oversight rather than public fund documentation. The lack of a regularly updated public website or LinkedIn profile further indicates governance built around tight LP relationships and Swiss private-equity norms of discretion.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: